Recombinant Human Albumin in Cell Culture-Safety, Consistency and Performance

Recombinant Human Albumin in Cell Culture: Safety, Consistency and Performance

As biologics manufacturing continues to shift toward defined and animal-origin-free (AOF) systems, traditional components such as serum and serum-derived proteins pose a unique challenge. Human and bovine serum albumin (HSA and BSA), commonly used in media and downstream buffers, can introduce variability, increase regulatory burden and carry a risk of contamination.

Why Replace Serum-Derived Albumin? In clinical and commercial biomanufacturing, there’s growing demand for raw materials that are:

• Chemically defined
• Free from animal and human origin (XENO-free)
• Consistent in composition
• Globally regulatory compliant

Recombinant human serum albumin (rHSA) provides a high-purity, reliable alternative to serum-derived proteins—without compromising function.

How Recombinant Albumin Is Used The diagram above shows how recombinant albumin is used across biologics workflows:

🔹 Cell Culture

• Enhances growth and viability of production cell lines (e.g., CHO, HEK293)
• Improves protein expression in serum-free and chemically defined media

🔹 Downstream Processing Buffers

• Stabilizes proteins during purification
• Reduces aggregation, oxidation and surface adsorption

🔹 Protein Formulation and Cryopreservation

• Prevents degradation and loss of activity
• Protects cells and proteins during freeze–thaw cycles

Why It Matters Replacing undefined, animal-derived materials with recombinant alternatives improves process control and de-risks clinical development. Recombinant albumin supports supply chain continuity and helps meet regulatory expectations across global markets.

Summary Recombinant albumin plays a key role in modern biologics manufacturing. Whether used in upstream culture, downstream purification or final formulation, it delivers the consistency, safety and performance needed for high-quality biotherapeutics.